Time for a Fully Integrated Nonclinical–Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective

Hugo M. Vargas(Amgen (United States)), Jean‐Pierre Valentin(UCB Pharma (Belgium)), Charles Benson(Eli Lilly (United States)), Yoshiko Okai(Takeda (Japan)), Stephen Jenkinson(Pfizer (United States)), Paul Lévesque(Bristol-Myers Squibb (United States)), Todd Wisialowski(St Vincent's Hospital), Anthony Bahinski, Gary A. Gintant(Abbott Fund), Armando Lagrutta(Oregon Health & Science University), Christa Hegele‐Hartung(Bayer (Germany)), Katsuyoshi Chiba(Daiichi-Sankyo (Japan)), Corina Dota(AstraZeneca (Sweden)), Eric Martel(Boehringer Ingelheim (Germany)), Amy Pointon(AstraZeneca (United Kingdom)), Andrea Greiter‐Wilke(Roche (Switzerland)), C. Michael Foley(AbbVie (United States)), Ravikumar Peri(Takeda (United States)), Martin Traebert(University of Zurich), William E. Achanzar(Bristol-Myers Squibb (Germany)), Nicolas Couvreur(Servier (France)), Yusheng Qu(Amgen (United States)), Michael G. Rolf(AstraZeneca (Sweden)), Khuram W. Chaudhary(GlaxoSmithKline (United States)), David J. Gallacher(University Hospital of Wales), Takashi Yoshinaga(Eisai (Japan)), Brian D. Guth(Boehringer Ingelheim (Germany)), Maki Ito(Japan Chemical Industry Association), Herbert M. Himmel(Bayer (Germany)), Michael J. Engwall(Amgen (United States)), Jean‐Michel Guillon(Sanofi (France)), Alan Bass(Merck & Co., Inc., Rahway, NJ, USA (United States)), Derek J. Leishman(Eli Lilly (United States)), Ard Teisman(Janssen (Belgium))
Clinical Pharmacology & Therapeutics
August 31, 2020
Cited by 96


Related Papers